Acutaas Chemicals Share Price

Pharmaceuticals company Acutaas Chemicals announced Q4FY26 & FY26 results Q4FY26 Consolidated Financial Highlights: Total Income: Rs 44,386.15 lakh in Q4FY26, compared to Rs 39,788.25 lakh in Q3FY26 (up 11.56% QoQ) and Rs 31,426.25 lakh in Q4FY25 (up 41.24% YoY). Revenue from Operations: Rs 43,275.05 lakh in Q4FY26, up from Rs 39,318.33 lakh in Q3FY26 (up 10.06% QoQ) and Rs 30,848.34 lakh in Q4FY25 (up 40.28% YoY). Profit Before Tax (PBT): Rs 18,380.17 lakh in Q4FY26, showing a growth of 27.05% QoQ from Rs 14,466.85 lakh and 121.89% YoY from Rs 8,283.44 lakh. Net Profit (PAT): Rs 13,428.37 lakh in Q4FY26, compared to Rs 10,621.92 lakh in Q3FY26 (up 26.42% QoQ) and Rs 6,271.61 lakh in Q4FY25 (up 114.11% YoY). FY26 Consolidated Financial Highlights: Total Income: Rs 1,38,095.20 lakh in FY26, compared to Rs 1,02,380.49 lakh in FY25, representing a YoY growth of 34.88%. Revenue from Operations: Rs 1,33,936.68 lakh in FY26, compared to Rs 1,00,687.55 lakh in FY25 (up 33.02% YoY). Profit Before Tax (PBT): Rs 48,272.57 lakh in FY26, marking a YoY growth of 123.32% from Rs 21,616.30 lakh in FY25. Net Profit (PAT): Rs 35,636.93 lakh in FY26, up from Rs 16,041.77 lakh in FY25 (up 122.15% YoY). Q4FY26 Standalone Financial Highlights: Total Income: Rs 43,631.82 lakh in Q4FY26, up from Rs 39,719.84 lakh in Q3FY26 (up 9.85% QoQ) and Rs 30,985.56 lakh in Q4FY25 (up 40.81% YoY). Revenue from Operations: Rs 42,177.23 lakh in Q4FY26, compared to Rs 39,085.56 lakh in Q3FY26 (up 7.91% QoQ) and Rs 30,416.14 lakh in Q4FY25 (up 38.67% YoY). Net Profit (PAT): Rs 13,707.12 lakh in Q4FY26, showing a growth of 22.86% QoQ from Rs 11,156.55 lakh and 118.11% YoY from Rs 6,284.68 lakh. FY26 Standalone Financial Highlights: Total Income: Rs 1,36,967.05 lakh in FY26, up 35.86% YoY from Rs 1,00,817.02 lakh in FY25. Revenue from Operations: Rs 1,32,379.22 lakh in FY26, compared to Rs 98,983.46 lakh in FY25 (up 33.74% YoY). Net Profit (PAT): Rs 36,617.45 lakh in FY26, compared to Rs 15,954.62 lakh in FY25 (up 129.51% YoY). Business Highlights Segment-wise Performance: The company operates in a Single Segment only. As per verbatim from the notes: "As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments." Dividend: The Board of Directors recommended a final dividend of Rs 2.5 per share (50%) on equity shares of face value of Rs 5 each for the FY 2025-26. Material Subsidiary: Based on latest audited consolidated financial statements, Indichem INC has met prescribed thresholds and is identified as a Material Subsidiary of the company. Joint Venture Investment: Acutaas Advance Material Limited (AAML), a wholly-owned subsidiary, entered into a joint venture with J & Materials Co. Ltd. (South Korea). AAML has made an investment of approximately Rs 190.52 crore in Indichem Inc. to acquire a 75% equity stake. Share Capital Change: During FY 2024-25, the company approved a sub-division of each equity share of face value of Rs 10 into two equity shares of face value of Rs 5 each. The record date for the split was April 25, 2025. Labour Code Assessment: The company assessed the impact of the new four Labour Codes. Verbatim from standalone notes: "the Company has assessed the impact of these changes and no material impact has been noticed under employee benefit expenses in the standalone audited financial results for the quarter | year ended on March 31, 2026." Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals, said: “I am pleased to report a strong close to FY26, with Q4 revenue from operations reaching Rs 4,328 million — up 40.3% YoY — and our highest ever PAT margin of 31.0%. Our strategy is clear: build a diversified chemicals business across three high-growth verticals — Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. By scaling these in parallel, we are de-risking our revenue base while creating multiple independent engines of compounding, long-term growth. We enter FY27 from a position of strength. I am confident of delivering 25% revenue growth in FY27.” Result PDF

• Trendlyne
• 1 month ago

Conference Call with Acutaas Chemicals Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 4 months ago

Pharmaceuticals company Acutaas Chemicals announced Q3FY26 results Revenue from operations for Q3FY26 grew by 43.0% YoY to Rs 3,932 million. The gross margin for the quarter improved to 57.0%, up 1,073 bps YoY. EBITDA for the quarter came at Rs 1,507 million, up 119.4% YoY. EBITDA margin for the quarter was at 38.3% as compared to 25.0% in Q3FY25. PAT for the quarter was Rs 1,062 million, up 133.7% as compared to PAT of Rs 454 million in Q3FY25. The PAT margin for the quarter was at 27.0,% up 1,049 bps YoY. Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals, said: “We continue to reinforce our core pharmaceutical intermediates business through the addition of CMO/CDMO opportunities alongside strengthening our business foundation by scaling battery chemicals and semiconductor chemicals verticals. These businesses, which are currently under active capital investment, are progressing steadily toward scale. Over the next three years, we expect each vertical to operate as an independent, self-sustaining growth engine, contributing meaningfully to our overall topline. I am pleased to share that we have sustained strong growth momentum in Q3, driven by the continued ramp-up of our CDMO business. As we progress toward the end of the financial year, supported by a healthy order book and improved visibility, we are revising our revenue growth guidance upward—from 25% to approximately 30%.” Result PDF

• Trendlyne
• 4 months ago